30-Oct-2026 18:55:27
FABTECH TECHNOLOGIES Q2 CONCALL: RETAINS FY27 GROWTH GUIDANCE & 8–9% ADJUSTED PAT MARGIN TARGET; ₹900 CR+ ORDER BOOK, ₹3,600–4,000 CR BID PIPELINE, EXPECTS ₹800–850 CR NEW ORDERS IN 12 MONTHS & TARGETS 25–30% LONG-TERM GROWTH
• FY27 Revenue Growth Guidance: Management maintained its earlier 20–25% annual revenue growth guidance, expecting significant improvement in H2 FY27 through faster project execution. • Long-Term Revenue Growth Guidance: Management targets approximately 25–30% annual growth over the next 3–5 years, supported by expansion across emerging markets, larger turnkey projects and new business verticals. • FY27 Adjusted PAT Margin Guidance: Management reiterated its target of approximately 8–9% adjusted PAT margin for FY27, excluding exceptional gains. • H2 FY27 Revenue Outlook: Management expects revenue execution to accelerate significantly during H2 as project milestones progress, with Q4 traditionally contributing the highest share. • H2 FY27 Profitability Outlook: Management expects improved operating leverage, better project execution and procurement efficiencies to support margins during the second half. • FY27 Guidance Confidence: Management expressed confidence in achieving annual targets despite weaker YoY revenue performance during H1, citing its existing order book and projects under execution. • Order Book: Outstanding order book remained above ₹900 Cr as of September 2026, representing approximately 2.2 times the previous year's revenue. • Executable Order Book: Management indicated that approximately ₹700 Cr of the ₹900 Cr order book has received commercial clearance and progressed to detailed engineering and execution planning. • Order Book Composition: Approximately 70% of order value comes from large projects, while smaller projects contribute the remaining 30% and support faster execution. • New Order Inflow Guidance: Management expects approximately ₹800–850 Cr of additional orders over the next 12 months, primarily from Middle Eastern and African markets. • Active Bid Pipeline: Management indicated that its active project pipeline stands at approximately ₹3,600–4,000 Cr. • Order Conversion Outlook: Management expects ₹800–850 Cr of opportunities to convert into firm orders over the coming year, subject to customer approvals and project finalization. • Order Book Replenishment: Management aims to maintain a healthy order book through continued project wins while converting existing orders into revenue. • Africa Growth Outlook: Management expects Africa to become a major contributor to future order inflows and revenue, supported by investments in domestic pharmaceutical manufacturing. • Saudi Arabia Growth Outlook: Management expects Saudi Arabia to remain a key market, driven by healthcare infrastructure localization, pharmaceutical investments and new industrial projects. • UAE Business Outlook: Management is focusing on accelerating project execution and business development in the UAE while maintaining customer commitments despite geopolitical disruptions. • CIS Market Expansion: Company is entering the CIS region through a new turnkey pharmaceutical design-and-build project, expanding its international reference base. • European Acquisition Timeline: Management expects its proposed European acquisition to progress toward completion within approximately six months or during Q1 FY28, subject to due diligence and approvals. • European Acquisition Strategy: The proposed acquisition aims to provide local manufacturing capabilities, product diversification, established customer relationships and European project references. • European Procurement Advantage: Management expects European manufacturing capabilities to improve its ability to participate in internationally funded projects requiring European sourcing. • Order Conversion Benefits: Management believes the proposed European acquisition could improve tender conversion rates by strengthening technical references and access to international procurement networks. • US Market Expansion: Management sees the proposed European acquisition as a potential gateway for expanding its presence in the US pharmaceutical and healthcare infrastructure market. • Saudi Joint Venture Expansion: Management is progressing discussions and operational arrangements for additional Saudi business opportunities, including critical electromechanical and non-pharmaceutical projects. • Saudi JV Announcement Outlook: Management indicated that further details of its Saudi joint venture initiatives could be announced over the next quarter as operating structures and management teams are finalized. • Saudi Industrial Project Opportunities: Company is pursuing large-ticket projects related to Saudi Aramco, SABIC and government-linked industrial infrastructure. • Pre-Engineered Buildings Expansion: Company is entering the PEB and civil infrastructure segment to offer broader turnkey project capabilities. • PEB Business Opportunity: Management indicated that approximately 20% of its broader project pipeline could involve PEB-related scope. • PEB Revenue Timeline: Management expects the new PEB business to mature gradually, with potential revenue contribution during H2 FY27 or H1 FY28 depending on project conversions. • PEB Margin Outlook: Management has not provided specific profitability guidance for the business, noting that its commercial and execution model remains under development. • Data Center Business Expansion: Company is bidding for critical infrastructure projects in Saudi Arabia, Oman and the UAE, supported by growing regional data center investments. • Data Center Addressable Scope: Management estimates Fabtech can undertake approximately 30% of a typical data center project's value through HVAC, MEP, cleanroom-related infrastructure and project management integration. • Data Center Project Strategy: Company is targeting specialized infrastructure rather than data management systems, AI systems, security infrastructure or standalone civil construction. • Advanced Technology Expansion: Management is developing capabilities in cell and gene therapy facilities, high-containment systems and other specialized pharmaceutical manufacturing infrastructure. • Non-Pharma Diversification: Company is exploring projects in food and beverages, electrical manufacturing, lens manufacturing, diapers, baby products and other industries requiring controlled infrastructure. • Pharma Infrastructure Market: Management estimates the global turnkey pharmaceutical and biotechnology project market at approximately $180 billion, growing around 8% annually. • Core Geographic Opportunity: Management estimates the serviceable market across GCC, Africa and MENA at approximately $28–30 billion. • Saudi Pharma Investment Opportunity: Management highlighted more than $15 billion of potential pharmaceutical manufacturing investment under Saudi Vision 2030. • Africa Pharma Investment Opportunity: Management cited approximately $60 billion of planned medicine manufacturing investments across Africa through 2040. • Pharma Project Revenue Opportunity: Management indicated that Fabtech's integrated engineering and infrastructure scope can represent approximately 50% of a typical pharmaceutical manufacturing project. • Manufacturing Localization Strategy: Company is focusing on countries seeking domestic vaccine, pharmaceutical, biotechnology and healthcare manufacturing capabilities. • Integrated Project Delivery: Fabtech provides end-to-end design, engineering, manufacturing, installation, commissioning and validation services across pharmaceutical and healthcare facilities. • In-House Manufacturing Contribution: Management indicated that approximately 30% of the value of an integrated design-and-build project typically involves products manufactured internally. • Engineering Services Contribution: Management indicated that detailed design and engineering activities broadly represent around 10% of the project value, although these services are not reported separately. • Project Execution Strategy: Company is focusing on larger integrated turnkey projects rather than standalone engineering or individual equipment contracts. • Manufacturing Capabilities: Company manufactures and integrates pharmaceutical process equipment, cleanrooms, HVAC systems, utilities, purified water systems, containment equipment and sterile manufacturing infrastructure. • Global Execution Network: Company has executed more than 500 projects and 2,000 installations across over 62 countries. • Regional Operating Presence: Company maintains engineering and manufacturing operations in India, regional operations in the UAE, a Saudi joint venture and teams across several African and Middle Eastern markets. • Procurement Margin Improvement: Management expects alternate sourcing, pooled procurement and local vendor development to improve project profitability. • Procurement Savings Potential: Management indicated that alternative sourcing initiatives could create approximately 2–3% margin improvement potential over time. • Localization Benefits: Management expects local sourcing and regional execution teams to reduce costs, improve project competitiveness and support margin expansion over the next 2–3 years. • Margin Expansion Strategy: Management identified globalization, alternative sourcing and larger project scope as major drivers of long-term margin improvement. • Order Book Profitability: Management indicated that margins vary by project and geography, with the blended profitability of new orders expected to remain broadly comparable to existing levels. • Strategic Project Pricing: Company may accept lower margins on selected high-value reference projects to establish capabilities and secure future business in new markets. • Revenue Recognition Strategy: Management is evaluating changes to its revenue recognition approach in consultation with auditors and advisers, with possible implementation during FY28. • Quarterly Revenue Volatility: Management expects project milestone timing to continue influencing quarterly performance, particularly in the absence of a revised revenue recognition framework. • Geopolitical Disruption: Higher freight costs, raw material inflation and additional employee security expenses affected project execution costs during H1. • Project Execution Continuity: Management indicated that existing customer commitments remain operational despite geopolitical and logistics challenges. • Order Conversion Delays: Management acknowledged that geopolitical uncertainty has delayed certain project conversions, although it has not resulted in cancellation of the overall opportunity pipeline. • Customer Payment Security: Management indicated that a substantial proportion of international receivables is supported by letters of credit. • Receivables Collection Outlook: Management expects significant customer collections during Q3 and Q4 FY27 as project milestones are completed and payment processes progress. • Gross Receivables: Group receivables stood at approximately ₹235 Cr as of September 2026. • Net Receivables: After ECL provisions, receivables stood at approximately ₹226 Cr, comprising ₹145 Cr not yet due and ₹81 Cr overdue. • Overdue Receivables: Approximately ₹25 Cr of overdue receivables relates to retention money, while management is pursuing collection of roughly ₹50 Cr over the next few months. • Operating Cash Flow Outlook: Management targets a return to positive operating cash flow by March 2027, supported by improved collections and conversion of work-in-progress into revenue. • Working Capital Investment: Other current assets increased from approximately ₹35 Cr to ₹75 Cr, mainly due to higher vendor advances for H2 project execution. • Vendor Advances: Management indicated that approximately ₹38 Cr of the increase in other current assets relates to advances paid for materials and equipment. • Cash Position: Management indicated that cash and bank balances exceeded ₹200 Cr, including unutilized IPO proceeds. • IPO Proceeds Utilization: Management expects planned IPO fund deployment toward working capital, general corporate purposes and inorganic growth to be substantially completed by FY27-end. • Capital Allocation Strategy: Surplus cash may be deployed toward acquisitions, working capital requirements and operating efficiency initiatives. • ROE Outlook: Management indicated that ROE currently stands near 9%, with an aspiration to improve returns toward 20–30% over the next 2–3 years as the business scales. • Q2 Revenue Performance: Consolidated revenue from operations increased 22.8% QoQ to ₹92.09 Cr, compared with ₹74.98 Cr in Q1. • Q2 Total Income: Total income increased 24.8% QoQ to ₹97.54 Cr. • Q2 EBITDA Performance: EBITDA increased approximately 110% QoQ to ₹15.57 Cr, compared with ₹7.41 Cr in Q1. • Q2 EBITDA Margin: Reported EBITDA margin expanded to 16% from 9.5% QoQ, an improvement of approximately 647 bps. • Q2 Reported Net Profit: PAT increased to ₹15.02 Cr from ₹4.21 Cr QoQ, supported partly by an exceptional gain. • Q2 Exceptional Gain: Reported PAT included an exceptional item of approximately ₹6.59 Cr, net of tax. • Q2 Adjusted Net Profit: Excluding the exceptional item, adjusted PAT stood at approximately ₹8.45 Cr, compared with ₹4.21 Cr in Q1. • Q2 Adjusted PAT Margin: Margin improved to approximately 9.2% from 5.6% QoQ, an expansion of around 354 bps. • Geographic Revenue Performance: Management reported Saudi Arabia revenue of approximately ₹46.2 Cr, up 18.5% YoY, while Morocco, Kenya and Algeria together contributed approximately ₹47 Cr during the period discussed. • India Revenue Contribution: Management indicated that India accounted for approximately 16% of revenue, reflecting improvement in its standalone operations. • Key Challenges: H2-dependent revenue growth, uneven project milestone recognition, geopolitical disruptions, elevated receivables, working capital requirements, acquisition execution, new business incubation and maintaining margins across international projects remain important factors.
FABTECH TECHNOLOGIES LTD